Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 2/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18819884 | 0.81 | CCR1 (0.33) | F2RL1 | |
| SCHEMBL22509829 | 0.80 | F2RL1 (0.36) | F2RL1RHEB | |
| SCHEMBL30592408 | 0.80 | F2RL1 (0.36) | F2RL1RHEBHTR1DHTR1B | |
| SCHEMBL21985982 | 0.78 | BRD4 (0.33) | — | |
| SCHEMBL14981460 | 0.71 | F2RL1 (0.36) | F2RL1RHEBHTR1DHTR1B | |
| SCHEMBL23937726 | 0.70 | COMT (0.33) | F2RL1 | |
| SCHEMBL23107523 | 0.70 | NOTUM (0.35) | F2RL1RHEB | |
| SCHEMBL26536818 | 0.70 | — | — | |
| SCHEMBL27285038 | 0.70 | HSD11B1 (0.33) | — | |
| SCHEMBL18876112 | 0.68 | HTR1D (0.37) | F2RL1RHEBHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | F2RL1 3421/4885RHEB 560/4885HTR1D 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.